ACAD

ACADIA PHARMACEUTICALS INC

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001070494
$21.41 -1.97% $3.7B
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)4 New Institutional Positions
Vol
Market Cap$3.7B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (78%)
Inst. Holders9 funds
Inst. Value$635.3M
Inst. Activity4 buys / 0 sells
Insider Activity0B / 12S
Insider Net $-$909.0K
SEC Reports5
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001070494·Prev Close $21.84

Recent Activity

May 29, 2026 Insider
Ndu Adora sold 9,311 shares
Director @ $0.00 ($0.00)
May 29, 2026 Insider
Ndu Adora sold 16,004 shares
Director @ $0.00 ($0.00)
May 29, 2026 Insider
Ndu Adora sold 8,107 shares
Director @ $0.00 ($0.00)
May 6, 2026 SEC
Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) and revenue of $268M (
8-K — Impact 6/10
May 6, 2026 earnings_calendar
ACAD Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026 SEC
Two ACAD insiders (CFO and principal accounting officer) sold small open-market positions totaling ~$105K on May 4, 2026
CLUSTER — Impact 2/10
Mar 27, 2026 SEC
Multiple C-suite executives at Acadia Pharmaceuticals, including the CEO, CFO, and other senior officers, conducted open
CLUSTER — Impact 4/10
Inst.
NORGES BANK — NEW
1,507,527 shares ($40.3M)

Price Targets

$31.65 +47.8% upside Strong Buy
Current $21.41 Low $17.00 Median $32.00 High $45.00 20 analysts
$17.00 $45.00

Analyst Ratings

Buy78% buy · 27 analysts
7Strong Buy
14Buy
5Hold
1Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 8, 2026 Citigroup MAINTAIN Buy → Buy
Mar 25, 2026 B of A Securities UPGRADE Neutral → Buy
Mar 4, 2026 JP Morgan MAINTAIN Overweight → Overweight
Feb 26, 2026 TD Cowen MAINTAIN Buy → Buy
Feb 26, 2026 RBC Capital MAINTAIN Outperform → Outperform

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.04 ▼ -66.2% $-0.05 — $0.12 -76% YoY 11
Next Q $0.12 ▲ +1.9% $0.08 — $0.15 -71% YoY 11
Current FY $0.40 ▼ -18.0% $0.23 — $0.74 -52% YoY 12
Next FY $0.89 ▼ -5.9% $0.50 — $1.70 125% YoY 11

Latest Reports

BEARISH 8-K 6/10
Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) and revenue of $268M (
May 6, 2026
NEUTRAL CLUSTER 2/10
Two ACAD insiders (CFO and principal accounting officer) sold small open-market positions totaling ~$105K on May 4, 2026
May 5, 2026

Top Institutional Holders

FundValueMove
VANGUARD GROUP INC$404.8M—
RENAISSANCE TECHNOLOGIES LLC$40.9MDOUBLED
NORGES BANK$40.3MNEW
BANK OF AMERICA CORP$32.6MADD
CHARLES SCHWAB INVESTMENT MANAGEMENT$31.3MNEW

Recent Insider Trades

DateInsiderTypeValue
May 29, 2026Ndu AdoraA$0.00
May 29, 2026Ndu AdoraA$0.00
May 29, 2026Ndu AdoraM$0.00
May 29, 2026Ndu AdoraM$0.00
May 29, 2026HARRIGAN EDMUNDM$0.00
9 institutional holders with $635.3M total value (23,785,084 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, NORGES. Net buying activity: 4 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1VANGUARD GROUP INC15,153,957$404.8M63.7%—
2RENAISSANCE TECHNOLOGIES LLC1,532,596$40.9M6.4%DOUBLED +204.2%
3NORGES BANK1,507,527$40.3M6.3%NEW
4BANK OF AMERICA CORP /DE/1,221,445$32.6M5.1%ADD +37.6%
5CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,172,317$31.3M4.9%NEW
6MORGAN STANLEY1,141,974$30.5M4.8%TRIM -71.1%
7TWO SIGMA INVESTMENTS, LP1,119,117$29.9M4.7%ADD +68.1%
8FMR LLC726,963$19.4M3.1%DOUBLED +293.1%
9WELLS FARGO & COMPANY/MN209,188$5.6M0.9%ADD +38.7%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
NORGES BANKNEW—1,507,527—$40.3M2025-Q4
BANK OF AMERICA CORP /DE/ADD887,8481,221,445+37.6%$32.6M2025-Q4
TWO SIGMA INVESTMENTS, LPADD665,8911,119,117+68.1%$29.9M2025-Q4
WELLS FARGO & COMPANY/MNADD150,803209,188+38.7%$5.6M2025-Q4
MORGAN STANLEYTRIM4,111,2471,188,406-71.1%$25.4M2025-Q3
TWO SIGMA INVESTMENTS, LPADD483,098665,891+37.8%$14.2M2025-Q3
FMR LLCDOUBLED169,362665,810+293.1%$14.2M2025-Q3
NORGES BANKEXIT1,468,6470-100.0%$0.002025-Q3
NORGES BANKNEW—1,468,647—$31.7M2025-Q2
UBS Group AGTRIM1,056,850736,223-30.3%$15.9M2025-Q2
TWO SIGMA INVESTMENTS, LPTRIM816,656483,098-40.8%$10.4M2025-Q2
WELLS FARGO & COMPANY/MNTRIM199,745138,694-30.6%$3.0M2025-Q2
MORGAN STANLEYTRIM7,297,0494,680,183-35.9%$77.7M2025-Q1
TWO SIGMA INVESTMENTS, LPTRIM1,243,442816,656-34.3%$13.6M2025-Q1
FMR LLCADD138,025174,251+26.2%$2.9M2025-Q1
NORGES BANKEXIT1,392,6180-100.0%$0.002025-Q1
MORGAN STANLEYDOUBLED1,675,8547,297,049+335.4%$133.9M2024-Q4
UBS Group AGDOUBLED604,1521,241,275+105.5%$22.8M2024-Q4
RENAISSANCE TECHNOLOGIES LLCDOUBLED403,2001,226,533+204.2%$22.5M2024-Q4
CITADEL ADVISORS LLCADD278,162499,365+79.5%$9.2M2024-Q4
MORGAN STANLEYTRIM2,391,1051,675,854-29.9%$25.8M2024-Q3
CHARLES SCHWAB INVESTMENT MANAGEMENT INCNEW—1,271,135—$19.6M2024-Q3
12 unique insiders with 12 transactions. Net insider value: -$909.0K ($0.00 bought, $909.0K sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 29, 2026Ndu AdoraDirectorA9,311$0.00$0.00
May 29, 2026Ndu AdoraDirectorA16,004$0.00$0.00
May 29, 2026Ndu AdoraDirectorM8,107$0.00$0.00
May 29, 2026Ndu AdoraDirectorM8,107$0.00$0.00
May 29, 2026HARRIGAN EDMUNDDirectorM8,107$0.00$0.00
May 29, 2026HARRIGAN EDMUNDDirectorM8,107$0.00$0.00
May 29, 2026Daly James MDirectorM8,107$0.00$0.00
May 29, 2026Daly James MDirectorA16,004$0.00$0.00
May 29, 2026Daly James MDirectorM8,107$0.00$0.00
May 29, 2026GAROFALO ELIZABETH A.DirectorA9,311$0.00$0.00
May 29, 2026GAROFALO ELIZABETH A.DirectorM8,107$0.00$0.00
May 29, 2026HARRIGAN EDMUNDDirectorA16,004$0.00$0.00
May 29, 2026Poole JonathanDirectorA9,311$0.00$0.00
May 29, 2026Daly James MDirectorA9,311$0.00$0.00
May 29, 2026GAROFALO ELIZABETH A.DirectorA16,004$0.00$0.00
May 29, 2026Poole JonathanDirectorA16,004$0.00$0.00
May 29, 2026Poole JonathanDirectorM2,010$0.00$0.00
May 29, 2026Brege LauraDirectorA9,311$0.00$0.00
May 29, 2026Brege LauraDirectorA16,004$0.00$0.00
May 29, 2026Brege LauraDirectorM8,107$0.00$0.00
May 29, 2026Brege LauraDirectorM8,107$0.00$0.00
May 29, 2026HARRIGAN EDMUNDDirectorA9,311$0.00$0.00
May 29, 2026GAROFALO ELIZABETH A.DirectorM8,107$0.00$0.00
May 29, 2026Poole JonathanDirectorM2,010$0.00$0.00
May 29, 2026BAKER BROS. ADVISORS LPDirectorA32,008$0.00$0.00
May 29, 2026BAKER BROS. ADVISORS LPDirectorA18,622$0.00$0.00
May 26, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERSELL5,401$21.18$114.4K
May 4, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERSELL3,506$21.79$76.4K
May 4, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERSELL1,332$21.79$29.0K
May 1, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERM6,815$0.00$0.00
May 1, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERM6,815$0.00$0.00
May 1, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERM2,596$0.00$0.00
May 1, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERM2,596$0.00$0.00
Apr 7, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERSELL1,030$22.20$22.9K
Apr 7, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERSELL2,709$22.20$60.1K
Apr 5, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERM5,276$0.00$0.00
Apr 5, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERM5,276$0.00$0.00
Apr 5, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERM2,010$0.00$0.00
Apr 5, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERM2,010$0.00$0.00
Mar 26, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERSELL1,097$21.65$23.8K
Mar 26, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERSELL3,171$21.65$68.7K
Mar 25, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERSELL833$21.47$17.9K
Mar 25, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERM2,142$0.00$0.00
Mar 25, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERM2,142$0.00$0.00
Mar 25, 2026Owen Adams CatherineChief Executive OfficerSELL11,641$21.47$249.9K
Mar 25, 2026Rhodes Jennifer JEVP, CHIEF LEGAL OFFICER, SECSELL3,844$21.47$82.5K
Mar 25, 2026Thompson Elizabeth H.Z.EVP, Head of Research & DevSELL3,435$21.47$73.7K
Mar 25, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERM6,178$0.00$0.00
Mar 25, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERSELL4,177$21.47$89.7K
Mar 25, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERM6,178$0.00$0.00
5 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.6/10.
BEARISH 8-K 6/10
Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) an
May 6, 2026
NEUTRAL CLUSTER 2/10
Two ACAD insiders (CFO and principal accounting officer) sold small open-market positions totaling ~
May 5, 2026
NEUTRAL CLUSTER 4/10
Multiple C-suite executives at Acadia Pharmaceuticals, including the CEO, CFO, and other senior offi
Mar 27, 2026
NEUTRAL 8-K 3/10
Acadia Pharmaceuticals appointed Jonathan M. Poole to its board of directors and the Audit Committee
Mar 5, 2026
BULLISH 8-K 8/10
Acadia Pharmaceuticals reported strong fourth quarter and full year 2025 results, with GAAP revenue
Feb 25, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Buy (78% buy). Based on 27 analysts: 7 strong buy, 14 buy, 5 hold, 1 sell, 0 strong sell.

Analyst Price Targets

$31.65 mean target +47.8% upside Strong Buy (3.00)
$17.00 Low $45.00 High
MetricValue
Current Price$21.41
Target Low$17.00
Target Mean$31.65
Target Median$32.00
Target High$45.00
# Analysts20
RecommendationStrong Buy (3.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $0.04 $-0.05 $0.12 -76.2% -66.2% 1↑ 5↓ $0.3B 11.6% 11
Next Q
2026-09-30
 $0.12 $0.08 $0.15 -70.7% +1.9% 4↑ 2↓ $0.3B 16.8% 11
Current FY
2026-12-31
 $0.40 $0.23 $0.74 -52.1% -18.0% 1↑ 8↓ $1.2B 15.8% 12
Next FY
2027-12-31
 $0.89 $0.50 $1.70 124.8% -5.9% 1↑ 5↓ $1.4B 11.9% 11

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.038
7d ago$0.110-0.072
30d ago$0.113-0.075
60d ago$0.111-0.073
90d ago$0.197-0.159
12 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 8, 2026 Citigroup MAINTAIN Buy Buy
Mar 25, 2026 B of A Securities UPGRADE Neutral Buy
Mar 4, 2026 JP Morgan MAINTAIN Overweight Overweight
Feb 26, 2026 TD Cowen MAINTAIN Buy Buy
Feb 26, 2026 RBC Capital MAINTAIN Outperform Outperform
Feb 26, 2026 Citizens MAINTAIN Market Outperform Market Outperform
Feb 26, 2026 Stifel MAINTAIN Hold Hold
Feb 24, 2026 Wolfe Research INITIATE — Outperform
Feb 23, 2026 Mizuho UPGRADE Neutral Outperform
Feb 6, 2026 Oppenheimer MAINTAIN Perform Perform
Feb 3, 2026 RBC Capital MAINTAIN Outperform Outperform
Feb 3, 2026 Citizens REITERATE Market Outperform Market Outperform
Feb 3, 2026 HC Wainwright & Co. REITERATE Buy Buy
Jan 6, 2026 Citigroup MAINTAIN Buy Buy
Jan 6, 2026 UBS MAINTAIN Buy Buy
Dec 15, 2025 HC Wainwright & Co. MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 202671451078%
May 1, 202671451078%
Apr 1, 202671451078%
Mar 1, 202661461074%
Feb 1, 202651371069%
Jan 1, 202651371069%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 6, 2026
earnings_calendar
ACAD Q1 2026 Earnings Scheduled — 2026-05-06
Apr 24, 2026
short_interest
FTD: ACAD — 25,749 shares ($0.6M) failed to deliver
Settlement: 20260424, Price: $22.11, FTD Value: $569,310.39, ACADIA PHARMACEUTICALS INC
Apr 17, 2026
short_volume
Short Volume: ACAD — 56.9% short (0.4M / 0.8M)
Short: 444,240 | Exempt: 300 | TRF Vol: 780,943 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
short_volume
Short Volume: ACAD — 56.7% short (0.3M / 0.6M)
Short: 349,618 | Exempt: 2,815 | TRF Vol: 616,870 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: ACAD — 62.6% short (0.4M / 0.6M)
Short: 375,376 | Exempt: 4,488 | TRF Vol: 599,320 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_volume
Short Volume: ACAD — 55.8% short (0.3M / 0.6M)
Short: 316,174 | Exempt: 1,915 | TRF Vol: 566,599 | Short Ratio: 55.8% | Off-exchange volume (dark pool + OTC)
Mar 25, 2026
short_volume
Short Volume: ACAD — 57.2% short (0.4M / 0.7M)
Short: 418,272 | Exempt: 6,036 | TRF Vol: 731,227 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Feb 25, 2026
earnings_calendar
ACAD Q4 2025 Earnings After Market Close — 2026-02-25
Feb 6, 2026
short_interest
FTD: ACAD — 33,067 shares ($0.8M) failed to deliver
Settlement: 20260206, Price: $23.46, FTD Value: $775,751.82, ACADIA PHARMACEUTICALS INC
Aug 5, 2025
FDA
DAYBUE
Supplemental Approval — Labeling — TROFINETIDE — SOLUTION — ORAL